Drug Discovery World

NOVEMBER 9, 2023

Engineering for higher avidity and multi-valency Following chairperson’s remarks from Bruce Keyt, PhD, CSO, R&D, IGM Biosciences, there will be three presentations in this session. Sara Majocchi, PhD, Discovery Program Leader, Light Chain Bioscience – Novimmune SA, on: ‘Bispecific antibody mediated, PD-L1-dependant, CD28 co-stimulation’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Delveinsight

DECEMBER 3, 2020

Janssen buys a new gene therapy aimed at reversing a severe disease, from Hemera Biosciences. It has been speculated that modifications to the epigenome drive cell ageing, especially a process known as DNA methylation, by which methyl groups are tagged onto DNA. of the time and negative results 99.98% of the time, as per Roche.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

NOVEMBER 13, 2023

Paul-Joseph Aspuria, PhD, Director, Cell Therapy, Cell Therapy, Synthekine, on: ‘SYNCAR: Engineered human IL-2/IL-2Rβ orthogonal pairs that selectively enhance CAR T cell anti-tumour efficacy in liquid and solid tumour models’.

Protein 59

Protein Antibody Engineer Scientist 59